Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin DE000BAY0017
Ticker BAYN.DE
Company BAYER
Currency
Price
Aware Investor Index (AII) 0.6193
Recommendation BUY
P/E 29.65
ROE 11.92 %
Capitalization 77,462,464,724 $
Dividend Yield 3.66 %
P/S 1.91
AII Position 272
P/E Position 385
ROE Position 305
Capitalization Position 117
Dividend Yield Position 144
Sales 35,015,000,000 €
10-Year Average Earnings 2,250,400,000 €
Shares Outstanding 872,107,808
Equity 18,875,000,000 €
Dividend per Share 2.8 €
Industry Pharmaceutical
Country Germany
BAYER Investor Relations Web Site http://www.investor.bayer.com/en/







Sales:

YEAR MONTH AMOUNT
2017 12 35,015,000,000.00 €
2016 12 34,943,000,000.00 €
2015 12 46,324,000,000.00 €
2014 12 42,239,000,000.00 €
2013 12 40,157,000,000.00 €
2012 12 39,760,000,000.00 €
2011 12 36,528,000,000.00 €
2010 12 35,088,000,000.00 €
2009 12 31,168,000,000.00 €
2008 12 32,918,000,000.00 €

Earnings:

YEAR MONTH AMOUNT
2017 12 2,900,000,000.00 €
2016 12 2,233,000,000.00 €
2015 12 4,110,000,000.00 €
2014 12 3,426,000,000.00 €
2013 12 3,189,000,000.00 €
2012 12 889,000,000.00 €
2011 12 1,125,000,000.00 €
2010 12 1,245,000,000.00 €
2009 12 2,226,000,000.00 €
2008 12 1,161,000,000.00 €

Equity:

YEAR MONTH AMOUNT
2017 12 18,875,000,000.00 €
2016 12 16,565,000,000.00 €
2015 12 24,265,000,000.00 €
2014 12 20,106,000,000.00 €
2013 12 13,888,000,000.00 €
2012 12 14,363,000,000.00 €
2011 12 13,888,000,000.00 €

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 872,107,808
2016 12 832,502,808
2015 12 826,947,808
2014 12 826,947,808
2013 12 826,947,808
2012 12 826,947,808
2011 12 826,950,000

 












Bloomberg News for BAYER:



Google News for BAYER:

The Pharma Letter - 12 hours ago
Ruling on cheaper AMD drug angers Bayer
German pharma major Bayer (BAYN: DE) has hit out at a UK court's judgement that it is potentially lawful to offer patients bevacizumab ...
The Pharma Letter - 17 hours ago
Three orphan medicines recommended for approval by EMA/CHMP
... Jivi (damoctocog alfa pegol), from German drug major Bayer (BAYN: DE) for the treatment of hemophilia A (congenital factor VIII deficiency),.
The Pharma Letter - 21 hours ago
String of Japanese drug approvals
Germany's Bayer (BAYN: DE) today said that the MHLW has approved Jivi (BAY94-9027) for the prophylactic treatment of hemophilia A for ...
The Pharma Letter - 13 Sep 2018
Executive musical chairs at Sanofi and Bayer
Effective November 1, Mr Weinand, who has been a member of the board of management of Germany's Bayer (BAYN: DE) and head of the ...
The Pharma Letter - 5 Sep 2018
Bayer blames Monsanto for further guidance drop
For the second quarter in a row, German life sciences company Bayer (BAYN: DE) has lowered its earnings guidance for the year in presenting ...
The Pharma Letter - 24 Aug 2018
New indication for Bayer's Xarelto
German life sciences group Bayer (BAYN: DE) had a welcome opportunity on Friday to talk about some news that did not involve potential ...
The Pharma Letter - 28 Aug 2018
Bayer and J&J see pathway for wider use of Xarelto despite ...
Bayer and J&J see pathway for wider use of Xarelto despite ... which has US marketing rights to the drug from Germany's Bayer *BAYN: DE).
The Pharma Letter - 30 Aug 2018
FDA approval for new hemophilia A treatment, Jivi
The US Food and Drug Administration (FDA) has approved Bayer's (BAYN: DE) Jivi (BAY94-9027, antihemophilic factor [recombinant] ...
Nasdaq - 7 Sep 2018
European Stocks in the Doldrums Amid Mixed Economic Results ...
On Frankfurt's DAX, chemicals and consumer goods company Bayer (BAYN.DE) was 3.2% lower, semiconductor manufacturer Infineon (IFX.
Nasdaq - 6 Sep 2018
European Stocks Open Lower as Drop in German Manufacturing ...
DE) was down by 1.3% and chemicals and consumer goods company Bayer (BAYN.DE) was 0.9% lower. And, on Paris' CAC-40, Sodexo (SW.


Back